Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05517655 · ClinicalTrials.gov registry record · Phase 4
BEGIN Novel ImagiNG Biomarkers
A Phase 4 study of Cystic Fibrosis, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
- 3
- Study locations
NCT05517655: Recruiting Phase 4 study of Cystic Fibrosis, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT05517655 is a Phase 4 study of Cystic Fibrosis that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 44 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05517655, a Phase 4 study of Cystic Fibrosis, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
- 3
- Study locations
Study Summary
To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).
Primary Outcome
For pulmonary MRI, the primary outcome measure is the change in 129Xe ventilation defect percentage (VDP) from pre-therapy baseline to the one-year follow-up visit.
Conditions Studied
Interventions
- DRUG 129Xe
Study Locations (3)
Kansas
- University of Kansas Medical Center - Kansas City
Ohio
- Carrie Stevens - Cincinnati
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 4 |
What NCT05517655 shows while recruiting
NCT05517655 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which 129Xe is the first listed.
NCT05517655 reports a single indexed study location in Kansas, Ohio, Virginia.
Frequently Asked Questions
What is clinical trial NCT05517655 about?
NCT05517655 is a clinical study titled "BEGIN Novel ImagiNG Biomarkers". To determine the treatment effect of triple-combination therapy in 6-8 year olds after presumed FDA approval, using rapid structural and functional pulmonary and abdominal MRI (UTE and 129Xe).
What is the current status of trial NCT05517655?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2022-05-01. Estimated completion is 2028-11-01.
What conditions does trial NCT05517655 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT05517655?
The interventions under investigation include: 129Xe (DRUG).
Who is sponsoring clinical trial NCT05517655?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05517655 being conducted?
This trial has 3 study locations across Kansas, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05517655's enrollment target sits among peer trials
44 95th of 169 higher than 74 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Markers of Osteoporosis in Cystic Fibrosis
RECRUITING · Phase 4
-
Estrogen Supplementation and Bone Health in Women With CF
RECRUITING · Phase 4
-
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
RECRUITING · Phase 4
-
Hyperpolarized Imaging for New Treatments
ACTIVE NOT RECRUITING · Phase 4
-
Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis
ACTIVE NOT RECRUITING · Phase 4
-
PR-018: An Open-Label, Safety Extension of Study PR-011
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI